Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 1/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22249523 | 0.88 | NPC1 (0.50) | GABRA2GABRB2KDM4EALDH1A1GAA | |
| SCHEMBL16386606 | 0.86 | KDM4E (0.51) | GABRA2GABRB2KDM4EALDH1A1GAA | |
| SCHEMBL22923944 | 0.86 | MEN1 (0.50) | KDM4EALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL3665276 | 0.86 | AXL (0.49) | GABRA2GABRB2KDM4EALDH1A1GAA | |
| SCHEMBL680256 | 0.81 | LMNA (0.44) | KDM4ELMNAKMT2AMEN1MAPT | |
| SCHEMBL17929126 | 0.81 | L3MBTL1 (0.50) | KDM4ELMNAKMT2AMEN1MAPT | |
| SCHEMBL22249472 | 0.80 | THRB (0.41) | KDM4ELMNAKMT2AMEN1MAPT | |
| SCHEMBL29812481 | 0.80 | THRB (0.41) | KDM4ELMNAKMT2AMEN1MAPT | |
| SCHEMBL23146884 | 0.80 | GABRA2 (0.49) | GABRA2GABRB2KDM4EALDH1A1GAA | |
| SCHEMBL30388175 | 0.78 | GABRA2 (0.50) | GABRA2GABRB2KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174666-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-3762392-B1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO LTD (KR) | 2024-05-15 | — | — | EP | disclosed |
| EP-3843850-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11780835-B2 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | ARRAY BIOPHARMA INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230172914-A1 | BIOMARKER-BASED THERAPEUTIC COMPOSITION | WELLMARKER BIO CO., LTD. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20230172914-A1 | BIOMARKER-BASED THERAPEUTIC COMPOSITION | WELLMARKER BIO CO., LTD. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20230172914-A1 | BIOMARKER-BASED THERAPEUTIC COMPOSITION | WELLMARKER BIO CO., LTD. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20230011441-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-11447500-B2 | Thienopyridine derivatives and pharmaceutical composition comprising same | WELLMARKER BIO CO., LTD. (KR) | 2022-09-20 | — | — | US | disclosed |
| US-20220288043-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO, LTD. (KR) | 2022-09-15 | — | — | US | disclosed |
| WO-2021045279-A1 | BIOMARKER-BASED THERAPEUTIC COMPOSITION | 웰마커바이오 주식회사 | 2021-03-11 | — | — | WO | disclosed |
| WO-2021045279-A1 | BIOMARKER-BASED THERAPEUTIC COMPOSITION | 웰마커바이오 주식회사 | 2021-03-11 | — | — | WO | disclosed |
| CN-111295386-A | Thienopyridine derivatives and pharmaceutical compositions containing the same | 伟迈可生物有限公司 | 2020-06-16 | — | — | CN | disclosed |
| US-20200079770-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. | 2020-03-12 | — | — | US | disclosed |
| WO-2020047184-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2019182274-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO., LTD. (KR) | 2019-09-26 | — | — | WO | disclosed |
| US-RE43878-E1 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2310382-B1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | LILLY CO ELI (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8030302-B2 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447500-B2 | Thienopyridine derivatives and pharmaceutical composition comprising same | MAP4K5, MAP4K2, MAP3K9 | GABRA2 2430/4885GABRB2 2799/4885KDM4E 2286/4885 |
| US-20230011441-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MERTK, MET | GABRA2 2529/4885GABRB2 2087/4885KDM4E 935/4885 |
| US-20230172914-A1 | BIOMARKER-BASED THERAPEUTIC COMPOSITION | KRAS, RET, NRAS | GABRA2 3846/4885GABRB2 3247/4885KDM4E 4540/4885 |
| US-20240174666-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MERTK, MET | GABRA2 2449/4885GABRB2 2013/4885KDM4E 951/4885 |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | MET, MYCBP, MYC | GABRA2 3688/4885GABRB2 2418/4885KDM4E 1545/4885 |
| US-20200079770-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MERTK, MET | GABRA2 2449/4885GABRB2 2013/4885KDM4E 951/4885 |
| US-20220288043-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | PRKACA, MAP4K5, MAPKAPK5 | GABRA2 3041/4885GABRB2 3345/4885KDM4E 2594/4885 |
| US-11780835-B2 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | RET, MERTK, MET | GABRA2 2529/4885GABRB2 2087/4885KDM4E 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.